Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 48, 3657-3660, July 1, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allalunis-Turner, M. J.
Right arrow Articles by Siemann, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allalunis-Turner, M. J.
Right arrow Articles by Siemann, D. W.

Comparison of Glutathione Levels in Rodent and Human Tumor Cells Grown in Vitro and in Vivo1

M. Joan Allalunis-Turner2, Francis Y. F. Lee and Dietmar W. Siemann3

Division of Experimental Therapeutics and Department of Radiation Oncology, University of Rochester Cancer Center, Rochester, New York 14642

Cellular glutathione (GSH) levels were compared in human and rodent tumor cells grown both in vivo and in vitro. Three human (A431, HEp3, ME180) and two murine (KHT and RIF-1) tumor cell lines were used. The average GSH contents for exponentially growing human cells in vitro were 14.2, 10.9, and 17.0 fmol/cell for ME180, A431, and HEp3 cells, respectively. These cells also were grown as tumors in nude mice. Following dissociation, >90% pure populations of neoplastic and nonneoplastic cells were isolated by centrifugal elutriation prior to GSH determination. The data showed that the GSH levels of the tumor associated host cells were appreciably lower than those of the neoplastic cells. In addition, in contrast to the values obtained for the exponential cells, neoplastic cells grown in vivo showed a 2- to 3-fold reduction in GSH. However, the values for in vivo cells were similar to those obtained for the same tumor cells grown in vitro in the plateau phase. Compared to the human tumor cells the GSH contents of murine tumor cells always were lower. For example, RIF-1 and KHT cells in the exponential growth phase had GSH contents of 3.3 and 7.5 fmol/cell, respectively. Also, as was observed with the human cells, the GSH content of KHT cells in plateau phase of growth was 2–3 times less than that of cells in the exponential phase of growth. Similarly, the GSH content of KHT cells grown as in situ tumors prior to dissociation and isolation by centrifugal elutriation also was reduced by a factor of 3 compared to exponential phase cells. Although the average volume of tumor cells grown in vivo was less than that of cells grown in vitro, this did not account for the differences in GSH values observed when in vitro and in vivo derived cells were compared. Finally, GSH measurements made on multiple biopsies of individual human tumor xenografts varied by a factor of 2–3 within each tumor type studied. This variation, likely due to host cell fluctuations, may present a complicating feature in the interpretation of solid tumor GSH levels.

1 This research was supported by USPHS grants CA-11051 and CA-36858, awarded by the National Cancer Institute, Department of Health and Human Services. The support of the Cell Separation and Flow Cytometry Facility as well as the Animal Tumor Research/Xenograft Facility of the University of Rochester Cancer Center is gratefully acknowledged.

2 Recipient of a fellowship from the Alberta Heritage Foundation for Medical Research. Present address: Department of Radiobiology, Cross Cancer Institute, 11560 University Ave., Edmonton AB, Canada, T6G 1Z2.

3 To whom requests for reprints should be addressed, at University of Rochester Cancer Center, 601 Elmwood Ave., Box 704, Rochester, NY 14642, USA.

Received 9/21/87. Revised 1/29/88. Accepted 4/ 6/88.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. Gunnarsdottir, M. Rucki, and A. A. Elfarra
Novel Glutathione-Dependent Thiopurine Prodrugs: Evidence for Enhanced Cytotoxicity in Tumor Cells and for Decreased Bone Marrow Toxicity in Mice
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 77 - 86.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1988 by the American Association for Cancer Research.